Charles River Laboratories Acquires MPI Research
Pharmaceutical Technology's In the Lab eNewsletter
A $800-million acquisition of MPI Research expands Charles River's offerings for early-stage contract research.
Charles River Laboratories International announced on Feb. 13, 2018 that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, expanding its early-stage contract research offerings for the biopharmaceutical and medical device markets.
MPI, a Mattawan, MI-based non-clinical contract research organization (CRO), provides comprehensive testing services from its one-million-sq.-ft. facility. The acquisition will add ototoxicity and abuse liability capabilities to Charles River’s services, and will expand
existing capabilities in general and specialty toxicology, including ophthalmology, juvenile toxicity, molecular biology, and surgery, as well as medical device testing, Charles River reports.
In the announcement, Charles River reported strategic benefits of expanding its biotechnology client base, adding infrastructure for safety assessment, and generating revenue growth.
The transaction is expected to close in the second quarter of 2018, according to a Charles River press statement.
Source: Charles River Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
